• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Genprex Inc.

    10/3/24 10:09:50 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNPX alert in real time by email
    SC 13G 1 tm2425525d1_sc13g.htm SC 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C.  20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments

    Thereto Filed Pursuant to § 240.13d-2.

     

    Under the Securities Exchange Act of 1934

     

    Genprex Inc.

    (Name of Issuer)

     

              COMMON STOCK, PAR VALUE $0.001 PER SHARE         

    (Title of Class of Securities)

     

          372446203      

    (CUSIP Number)

     

                   September 30, 2024               

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨  Rule 13d-1(c)

    ¨  Rule 13d-1(d)

     

     

     

    Page 1 of 6 Pages

     

     

     

     

     

     

    CUSIP No.: 372446203 SCHEDULE 13G Page 2 of 6 Pages

     

    1)

    NAME OF REPORTING PERSON

     

    Forsakringsaktiebolaget Avanza Pension

     

    2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

    3)

    SEC USE ONLY

     

     

    4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Stockholm, Sweden

     

    NUMBER

    OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5)

    SOLE VOTING POWER

     

    130,648

     

    6)

    SHARED VOTING POWER

     

     

    7)

    SOLE DISPOSITIVE POWER

     

     

    8)

    SHARED DISPOSITIVE POWER

     

    130,648

     

    9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    130,648

     

    10)

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5,05 %

    12)

    TYPE OF REPORTING PERSON

     

    FI

             

     

     

     

    CUSIP No.: 372446203 SCHEDULE 13G Page 3 of 6 Pages

     

    Item 1(a). Name of Issuer:

     

    Genprex Inc.

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    1601 Trinity Street, Bldg. B, Suite 3.322

    AUSTIN, TX, 78712

    United States

     

    Item 2(a). Name of Person Filing:

     

    Forsakringsaktiebolaget Avanza Pension

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    Box 1399

    STOCKHOLM, 11139

    SWEDEN

     

    Item 2(c). Citizenship:

     

    Forsakringsaktiebolaget Avanza Pension is a company organized under the laws of Sweden

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, Par Value $0.001 per share

     

    Item 2(e). CUSIP Number:  372446203

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
           
      (c) ¨ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
           
      (d) ¨ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
           
      (e) ¨ Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
           
      (f) ¨ Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
           
      (g) ¨ Parent Holding Company or control person in accordance with §240.13d-1(b)(1)(ii)(G)
           
      (h) ¨ Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
           
      (i) ¨ Church plan that is excluded from the definition of an investment company under §3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)

     

     

     

      

    CUSIP No.: 372446203 SCHEDULE 13G Page 4 of 6 Pages

     

      (j) x A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)
           
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K)

     

    Item 4. Ownership.

     

      (a) Amount beneficially owned:  130,648

     

      (b)

    Percent of class: 5,05 %

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote:  130,648

     

      (ii) Shared power to vote or to direct the vote:  None

     

      (iii) Sole power to dispose or to direct the disposition of:  None

     

      (iv) Shared power to dispose or to direct the disposition of: 130,648

     

      Number and Percentage
    of Shares Beneficially Owned
      Date
      5,05 % / 130,648   October 3, 2024

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

     

     

    CUSIP No.: 372446203 SCHEDULE 13G Page 5 of 6 Pages

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

     

     

     

    CUSIP No.: 372446203 SCHEDULE 13G Page 6 of 6 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a Swedish insurance company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

    SIGNATURE

     

    After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

    October 3, 2024  
       
     /s/ Marie Karlsfeldt  
       
    Marie Karlsfeldt / Middle Office  
    Name/Title  

     

     

     

    Get the next $GNPX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNPX
    SEC Filings

    View All

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    2/10/26 8:04:05 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    1/9/26 4:58:44 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Genprex Inc.

    S-8 - Genprex, Inc. (0001595248) (Filer)

    1/9/26 4:56:14 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    National Securities initiated coverage on Genprex with a new price target

    National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00

    1/26/21 7:48:53 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moreno Toscano Jose Antonio was granted 9,000 shares, increasing direct ownership by 5,732% to 9,157 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    12/23/25 5:35:59 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Berger Mark Stanley was granted 28,500 shares, increasing direct ownership by 7,917% to 28,860 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    12/23/25 5:35:14 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO and CFO Confer Ryan M. was granted 45,000 shares, increasing direct ownership by 6,808% to 45,661 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    12/23/25 5:34:21 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

    Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® Company Adds Additional Acclaim-3 Clinical Trial Site AUSTIN, Texas, Feb. 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that IP Australia, the Australian government agency responsible for administering Australia's intellectual property rights system, has issued a Notice of Acceptance, on February 5, 2026, of the Genprex patent application claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodie

    2/10/26 8:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Provides Clinical Update on Diabetes Gene Therapy Program

    Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a clinical program update on its diabetes gene therapy program for GPX-002, the Company's diabetes gene therapy drug candidate, detailing recent achievements and future advancements. This update follows the recent announcement of positive preliminary preclinical data from studies of GPX-002 in both mouse and non-human primate (NHP) models, specifica

    1/7/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Leadership Updates

    Live Leadership Updates

    View All

    Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

    Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,

    5/13/24 8:31:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

    Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy

    8/22/23 7:30:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Genprex Inc.

    SC 13G/A - Genprex, Inc. (0001595248) (Subject)

    10/24/24 12:23:37 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/22/24 12:01:59 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/3/24 10:09:50 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care